Susan M O'brien

List of Publications by Year
in descending order

129 papers	22,298 citations	20797 60 h-index	16636 123 g-index
130 all docs	130 docs citations	130 times ranked	13597 citing authors

#	Article	IF	Citations
1	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2013, 369, 32-42.	13.9	2,019
2	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2014, 370, 997-1007.	13.9	1,535
3	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. New England Journal of Medicine, 2014, 371, 213-223.	13.9	1,427
4	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 2018, 131, 2745-2760.	0.6	1,069
5	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2016, 375, 740-753.	13.9	1,047
6	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2015, 16, 57-66.	5.1	1,031
7	Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 4079-4088.	0.8	899
8	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2016, 374, 323-332.	13.9	785
9	Three-year follow-up of treatment-naÃ¯ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 2015, 125, 2497-2506.	0.6	618
10	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 2012, 119, 1182-1189.	0.6	564
11	Ibrutinibâ€“Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2019, 381, 432-443.	13.9	545
12	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood, 2016, 127, 303-309.	0.6	441
13	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncology, The, 2014, 15, 48-58.	5.1	438
14	Inotuzumab ozogamicin, an anti-CD22â€“calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncology, The, 2012, 13, 403-411.	5.1	401
15	Chronic lymphocytic leukaemia. Nature Reviews Disease Primers, 2017, 3, 16096.	18.1	363
16	Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosomeâ€“Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3880-3889.	0.8	361
17	Single-agent ibrutinib in treatment-naÃ¯ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood, 2018, 131, 1910-1919.	0.6	339
18	Final analysis from RESONATE: Up to six years of followâ€up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 2019, 94, 1353-1363.	2.0	305

#	Article	IF	Citations
19	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood, 2015, 125, 2062-2067.	0.6	303
20	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood, 2017, 129, 572-581.	0.6	285
21	Management of adverse events associated with idelalisib treatment: expert panel opinion. Leukemia and Lymphoma, 2015, 56, 2779-2786.	0.6	268
22	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 3441-3452.	0.8	266
23	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer, 2013, 119, 2728-2736.	2.0	265
24	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood, 2016, 127, 1863-1869.	0.6	253
25	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood, 2014, 123, 1810-1817.	0.6	246
26	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology, The, 2015, 16, 1547-1555.	5.1	245
27	A phase 2 study of idelalisib plus rituximab in treatment-naÃ¯ve older patients with chronic lymphocytic leukemia. Blood, 2015, 126, 2686-2694.	0.6	224
28	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinibâ€based regimens. Cancer, 2015, 121, 3612-3621.	2.0	220
29	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	0.6	214
30	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and longâ€term survival followâ€up from the randomized, phase 3 INOâ€VATE study. Cancer, 2019, 125, 2474-2487.	2.0	210
31	Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Clinical Oncology, 2009, 27, 904-910.	0.8	203
32	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 2017, 102, 1796-1805.	1.7	200
33	Duvelisib, a novel oral dual inhibitor of PI3K-Î´,Î³, is clinically active in advanced hematologic malignancies. Blood, 2018, 131, 877-887.	0.6	199
34	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 240-248.	5.1	192
35	Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2012, 30, 2820-2822.	0.8	182
36	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood, 2019, 133, 1011-1019.	0.6	168

#	Article	IF	Citations
37	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematology,the, 2017, 4, e387-e398.	2.2	158
38	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica, 2016, 101, 1524-1533.	1.7	154
39	Monoclonal antibodies in acute lymphoblastic leukemia. Blood, 2015, 125, 4010-4016.	0.6	144
40	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. Journal of Clinical Oncology, 2017, 35, 166-174.	0.8	131
41	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leukemia and Lymphoma, 2015, 56, 1643-1650.	0.6	130
42	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, 2020, 135, 1204-1213.	0.6	130
43	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood, 2016, 127, 1269-1275.	0.6	119
44	Evolution of CLL treatment â€" from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews Clinical Oncology, 2018, 15, 510-527.	12.5	114
45	Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer, 2008, 113, 2097-2101.	2.0	109
46	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer, 2010, 116, 5568-5574.	2.0	104
47	Longâ€term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer, 2017, 123, 2268-2273.	2.0	103
48	Minimal residual disease assessed by multiâ€parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 392-400.	1.2	102
49	Long-term outcomes for ibrutinibâ€"rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood, 2022, 140, 112-120.	0.6	93
50	Augmented Berlinâ€Frankfurtâ€MÃ¼nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer, 2014, 120, 3660-3668.	2.0	91
51	Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options. Current Oncology Reports, 2012, 14, 387-394.	1.8	83
52	Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	83
53	Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood, 2009, 113, 3168-3171.	0.6	82
54	Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. Journal of Clinical Apheresis, 1995, 10, 188-193.	0.7	75

#	Article	IF	Citations
55	Hyperâ€CVAD plus nelarabine in newly diagnosed adult Tâ€cell acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma. American Journal of Hematology, 2018, 93, 91-99.	2.0	74
56	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory <scp>B</scp>â€cell acute lymphoblastic leukemia. Cancer, 2017, 123, 294-302.	2.0	70
57	Initial treatment of CLL: integrating biology and functional status. Blood, 2015, 126, 463-470.	0.6	69
58	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. American Journal of Hematology, 2018, 93, 371-374.	2.0	68
59	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematology,the, 2018, 5, e411-e421.	2.2	66
60	Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Reviews, 2016, 30, 233-244.	2.8	63
61	Inotuzumab ozogamicin in combination with lowâ€intensity chemotherapy (miniâ€HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2019, 125, 2579-2586.	2.0	63
62	Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine, 2018, 10, .	5.8	61
63	Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood, 2016, 128, 233-233.	0.6	60
64	ATM gene deletion in patients with adult acute lymphoblastic leukemia. , 2000, 88, 1057-1062.		54
65	Chronic Myelogenous Leukemia, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1327-1340.	2.3	52
66	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncology, 2020, 16, 517-523.	1.1	52
67	Prognostic impact of pretreatment cytogenetics in adult <scp>P</scp>hiladelphia chromosomeâ€“negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer, 2017, 123, 459-467.	2.0	49
68	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 2021, 137, 3327-3338.	0.6	47
69	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 1991, 68, 1201-1207.	2.0	45
70	Duvelisib, an oral dual PI3Kâ€Î´,Î³ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal of Hematology, 2018, 93, 1318-1326.	2.0	45
71	Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer, 1993, 72, 2155-2160.	2.0	43
72	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INOâ€VATE. Cancer, 2018, 124, 1722-1732.	2.0	43

#	Article	IF	Citations
73	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e523-e533.	2.2	43
74	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematology,the, 2018, 5, e136-e146.	2.2	42
75	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leukemia Research, 2020, 97, 106432.	0.4	40
76	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 135-141.	0.2	37
77	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a <scp>CD</scp>22 monoclonal antibody. American Journal of Hematology, 2015, 90, 193-196.	2.0	35
78	The absolute percent deviation of <scp>IGHV</scp> mutation rather than a 98% cutâ€off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. British Journal of Haematology, 2018, 180, 33-40.	1.2	33
79	<scp>S</scp>ignificance of recurrence of minimal residual disease detected by multiâ€parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. American Journal of Hematology, 2017, 92, 279-285.	2.0	32
80	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Investigational New Drugs, 1999, 17, 89-95.	1.2	31
81	Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e314-e322.	1.8	28
82	Longâ€term efficacy of firstâ€line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: aâ€‰pooled analysis from four clinical trials. British Journal of Haematology, 2022, 196, 947-953.	1.2	28
83	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. American Journal of Hematology, 2015, 90, 769-773.	2.0	27
84	Outcomes with ibrutinib by line of therapy and postâ€ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 2019, 94, 554-562.	2.0	27
85	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Frontiers in Oncology, 2021, 11, 720704.	1.3	27
86	Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 1388-1395.	2.0	26
87	Survival of Young Patients with Chronic Lymphocytic Leukemia Failing Fludarabine Therapy: A Basis for the Use of Myeloablative Therapies. Leukemia and Lymphoma, 1995, 18, 493-496.	0.6	25
88	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€negative Bâ€cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150.	2.0	25
89	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 2021, 35, 3201-3211.	3.3	25
90	Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood, 2000, 96, 768-770.	0.6	25

#	Article	IF	Citations
91	Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€“hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038.	2.0	24
92	Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances, 2021, 5, 5415-5419.	2.5	24
93	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 3331-3331.	0.6	24
94	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Future Oncology, 2019, 15, 579-589.	1.1	23
95	Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies. Blood, 2019, 134, 3041-3041.	0.6	23
96	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia, 2021, 35, 3421-3429.	3.3	22
97	Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e317-e325.	1.8	17
98	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Advances, 2019, 3, 3033-3037.	2.5	16
99	Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood, 2021, 138, 2810-2827.	0.6	16
100	Novel agents in chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2016, 2016, 137-145.	0.9	14
101	Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood, 2019, 134, 357-357.	0.6	14
102	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. Blood, 2019, 134, 2723-2723.	0.6	14
103	Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 580-591.	1.8	13
104	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3721-3721.	0.6	13
105	Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood, 2019, 134, 823-823.	0.6	12
106	A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 395-400.e1.	0.2	11
107	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology, 2019, 94, 408-416.	2.0	11
108	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016, 128, 588-588.	0.6	11

#	Article	IF	Citations
109	Hyperâ€CVAD plus ofatumumab versus hyperâ€CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2021, 127, 3381-3389.	2.0	10
110	B cell receptor inhibition as a target for CLL therapy. Best Practice and Research in Clinical Haematology, 2016, 29, 2-14.	0.7	9
111	The safety of Brutonâ€™s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Expert Opinion on Drug Safety, 2017, 16, 1079-1088.	1.0	9
112	A phase <scp>II</scp> trial of eltrombopag for patients with chronic lymphocytic leukaemia (<scp>CLL</scp>) and thrombocytopenia. British Journal of Haematology, 2019, 185, 606-608.	1.2	8
113	Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. Expert Review of Hematology, 2020, 13, 871-883.	1.0	8
114	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2021, 62, 3278-3282.	0.6	7
115	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. Expert Review of Hematology, 2020, 13, 31-38.	1.0	5
116	Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD). Blood, 2019, 134, 1299-1299.	0.6	4
117	Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib. Blood, 2016, 128, 4390-4390.	0.6	4
118	Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population. Leukemia and Lymphoma, 2022, 63, 2992-2995.	0.6	4
119	Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. Blood, 2019, 134, 1344-1344.	0.6	3
120	A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy. Blood, 2019, 134, 2927-2927.	0.6	3
121	Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. American Journal of Hematology, 2015, 90, 967-969.	2.0	2
122	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. Blood, 2019, 134, 2582-2582.	0.6	2
123	First-line therapy for young patients with CLL. Hematology American Society of Hematology Education Program, 2016, 2016, 146-148.	0.9	1
124	MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL. Leukemia and Lymphoma, 2017, 58, 1498-1501.	0.6	1
125	ATM gene deletion in patients with adult acute lymphoblastic leukemia. , 2000, 88, 1057.		1
126	Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 2548-2548.	0.6	0

#	Article	IF	Citations
127	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Blood, 2020, 136, 42-43.	0.6	0
128	Clinical implications of the 2018 iwCLL Guidelines update. Clinical Advances in Hematology and Oncology, 2018, 16 Suppl 15, 1-16.	0.3	0
129	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1580-1588.	0.6	0